Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10592	Companies
224598	Keywords
153316	Articles
118797	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/06/2024 at 13:00, 2 years ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 2 years ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 2 years ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 2 years ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 2 years ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 2 years ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 2 years 1 month ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 2 years 1 month ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 2 years 1 month ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years 1 month ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Accesswire

Published on 06/18/2026 at 00:00, 6 hours 58 minutes ago

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Published on 06/17/2026 at 23:30, 7 hours 28 minutes ago

Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders
Published on 06/17/2026 at 22:50, 8 hours 8 minutes ago

International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/17/2026 at 22:30, 8 hours 28 minutes ago

Innodata Appoints Jayant Chauhan as Chief Financial Officer
Published on 06/17/2026 at 16:55, 14 hours 3 minutes ago

Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors

View all ACCESSWIRE

EQS Group

Published on 06/18/2026 at 06:40, 17 minutes ago

APES 2026: 2,000+ Chinese Source Factories, One-Stop Direct Sourcing -Maximizing Buyer Margins
Published on 06/18/2026 at 06:30, 27 minutes ago

Schindler Holding Ltd. increases ongoing share buyback program to up to CHF 700 million
Published on 06/18/2026 at 04:05, 2 hours 52 minutes ago

Hisense Brings Smarter Home Experiences to Families During the FIFA World Cup 2026™
Published on 06/18/2026 at 02:45, 4 hours 13 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Update on APAC matter
Published on 06/17/2026 at 21:40, 9 hours 17 minutes ago

Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon

Les Echos

Published on 06/17/2026 at 17:40, 13 hours 18 minutes ago

Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 22 hours 13 minutes ago

Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 19 hours ago

Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 2 days 7 hours ago

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 12 hours ago

Reporting on share buyback transactions carried out between June 8 and June 11, 2026

View all LES ECHOS COMFI WIRE